This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Tirzepatide parenteral

Updated 2 Feb 2023 | GLP-1 agonists


Injections of tirzepatide.

Drugs List

  • MOUNJARO 2.5mg/0.5ml solution for injection pre-filled pen
  • MOUNJARO 5mg/0.5ml solution for injection pre-filled device
  • tirzepatide 2.5mg/0.5ml solution for injection pre-filled device
  • tirzepatide 5mg/0.5ml solution for injection pre-filled device
  • Therapeutic Indications


    Type 2 diabetes (NIDDM) not controlled by diet,weight loss & exercise alone

    Treatment of adults with insufficient controlled type 2 diabetes mellitus:

    As monotherapy when metformin is considered inappropriate due to intolerance or contraindications.

    In combination with other glucose lowering medication including insulin where the existing regimen with diet and exercise does not provide adequate glycaemic control.



    Initial dose
    2.5mg once a week for 4 weeks.

    A dose increased of 2.5mg can occur after 4 weeks of the current dose.

    Maintenance dose
    5mg to 15mg once a week.

    Maximum dose is 15mg once a week.

    Additional Dosage Information

    When tirzepatide is used in combination with insulin or a sulfonylurea, a lower dose of insulin or a sulfonylurea may be considered to reduce the risk of hypoglycaemia.

    Missed dose
    Within 4 days
    Administer the missed dose as soon as possible.

    More than 4 days
    Skip the missed dose and administer the next scheduled dose.


    For subcutaneous injection into the abdomen, thigh or upper arm. Rotate injection sites between each dose.

    To be administered once a week at any time of the day, can be given with or without meals.


    Children under 18 years

    Precautions and Warnings

    Patients over 85 years
    Diabetic macular oedema
    Diabetic retinopathy
    End stage renal disease
    History of pancreatitis
    Proliferative diabetic retinopathy
    Severe gastrointestinal disorder
    Severe hepatic impairment
    Severe renal impairment

    For subcutaneous use only
    Monitor patient for hypoglycaemia if adjunct to insulin or sulfonylurea
    Advise patient to seek medical advice if symptoms of dehydration occur
    Advise patients to report symptoms of acute pancreatitis immediately
    Discontinue if pancreatitis is suspected
    Do not restart treatment following confirmation of pancreatitis
    Advise patient on fluid replacement if GI side effects occur
    Patient to inform DVLA if fitness to drive impaired or hypoglycaemic risk

    Pregnancy and Lactation


    Tirzepatide is contraindicated during pregnancy.

    The manufacturer does not recommend the use of tirzepatide during pregnancy. Animal studies have indicated reproductive toxicity.


    Tirzepatide is contraindicated during breastfeeding.

    The manufacturer states a decision must be made as to discontinue breastfeeding or tirzepatide taking into account the benefits of breastfeeding for the child and the benefits of the therapy for the mother. Presence of tirzepatide excretion in human milk is unknown, a risk to the newborn cannot be excluded.

    Side Effects

    Abdominal distension
    Abdominal pain
    Acute pancreatitis
    Elevated amylase levels
    Elevated serum lipase
    Gastroesophageal reflux disease
    Hypersensitivity reactions
    Increased heart rate
    Increased serum calcitonin
    Injection site reactions


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: December 2022

    Reference Sources

    Summary of Product Characteristics: Mounjaro 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg solution for injection in pre-filled pen. Eli Lilly and Company Limited. Revised September 2022.

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.